Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around...
Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around zero after USA Today reports that the FDA has approved its Qnexa/Qysemia diet drug. However, no other news organizations appear to have reported the story, and it's not on the FDA website. Update: the linked-story in this MC seems to have been taken down. Vivus shares -0.6%.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Feb 25, 2015)
at Benzinga.com (Feb 24, 2015)
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Dec 30, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs